IN2014DN10239A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10239A
IN2014DN10239A IN10239DEN2014A IN2014DN10239A IN 2014DN10239 A IN2014DN10239 A IN 2014DN10239A IN 10239DEN2014 A IN10239DEN2014 A IN 10239DEN2014A IN 2014DN10239 A IN2014DN10239 A IN 2014DN10239A
Authority
IN
India
Prior art keywords
relates
compounds
pde4
phosphodiesterase
inhibitors
Prior art date
Application number
Inventor
Elisabetta Armani
Carmelida Capaldi
Laura Carzaniga
Oriana Esposito
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of IN2014DN10239A publication Critical patent/IN2014DN10239A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly the invention relates to compounds that are derivatives of 1 phenyl 2 pyridinyl alkyl alcohols methods of preparing such compounds compositions containing them and therapeutic use thereof.
IN10239DEN2014 2012-06-04 2013-05-28 IN2014DN10239A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170714 2012-06-04
PCT/EP2013/060915 WO2013182451A1 (en) 2012-06-04 2013-05-28 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10239A true IN2014DN10239A (en) 2015-08-07

Family

ID=48670496

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10239DEN2014 IN2014DN10239A (en) 2012-06-04 2013-05-28

Country Status (11)

Country Link
US (1) US9440954B2 (en)
EP (1) EP2855450B1 (en)
KR (1) KR20150022789A (en)
CN (1) CN104334542A (en)
AR (1) AR091261A1 (en)
BR (1) BR112014029642A2 (en)
CA (1) CA2875421A1 (en)
HK (1) HK1205116A1 (en)
IN (1) IN2014DN10239A (en)
RU (1) RU2637945C2 (en)
WO (1) WO2013182451A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR20150092173A (en) 2012-12-05 2015-08-12 키에시 파르마슈티시 엣스. 피. 에이. Phenylethylpyridine derivatives as pde4-inhibitors
EP2928869B1 (en) 2012-12-05 2019-02-20 Chiesi Farmaceutici S.p.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
CA2893622A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Novel compounds
CN104822669A (en) 2012-12-05 2015-08-05 奇斯药制品公司 Phenylethylpyridine derivatives as PDE4-inhibitors
AR104829A1 (en) * 2015-06-01 2017-08-16 Chiesi Farm Spa AMINOESTER DERIVATIVES
AR104822A1 (en) * 2015-06-01 2017-08-16 Chiesi Farm Spa AMINOESTER DERIVATIVE
US12577217B2 (en) 2019-01-08 2026-03-17 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitor
JP7532385B2 (en) 2019-01-31 2024-08-13 杏林製薬株式会社 15-PGDH inhibitors
CN116082670B (en) * 2023-04-11 2023-06-27 中国人民解放军军事科学院军事医学研究院 Preparation method of acoustic response pseudo conjugated polymer nano particles containing quaternary phosphonium salt and application of nano particles in antibacterial field

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652868B1 (en) 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
EP1634606A1 (en) 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
EP2044023B1 (en) * 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
ES2478670T3 (en) * 2007-02-28 2014-07-22 Leo Pharma A/S New phosphodiesterase inhibitors
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
BR112014009471A2 (en) 2011-10-21 2017-04-18 Chiesi Farm Spa compounds, combination of a compound, pharmaceutical composition, use of a compound, device and kit

Also Published As

Publication number Publication date
EP2855450B1 (en) 2016-07-06
RU2014148316A (en) 2016-07-27
AR091261A1 (en) 2015-01-21
RU2637945C2 (en) 2017-12-08
US9440954B2 (en) 2016-09-13
WO2013182451A9 (en) 2014-02-06
US20130324501A1 (en) 2013-12-05
CN104334542A (en) 2015-02-04
KR20150022789A (en) 2015-03-04
HK1205116A1 (en) 2015-12-11
EP2855450A1 (en) 2015-04-08
WO2013182451A1 (en) 2013-12-12
BR112014029642A2 (en) 2017-06-27
CA2875421A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
IN2014DN10239A (en)
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JO3181B1 (en) Derivatives of 1-Phenly -2- Pyridinyl Alkyl alcohols as Phosphodiesterase
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX368959B (en) Heteroaryl inhibitors of pde4.
PH12017502141A1 (en) Compounds and their methods of use
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PH12014502699A1 (en) Pyrimidinyl tyrosine kinase inhibitors
WO2013003298A3 (en) Inhibitors of pde10
IN2015DN00127A (en)
NZ700928A (en) Dna-pk inhibitors
IN2013MN00501A (en)
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2016009352A (en) Quinoline-based kinase inhibitors.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
EA201590268A1 (en) ARYLACTAM KINASE INHIBITORS
MA39824A (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
IN2014DN08443A (en)
MX2016015959A (en) Carbamate derivatives which are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists.
MY168958A (en) Intermediates and processes for preparing compounds